darusentan (HMR-4005) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
darusentan (HMR-4005) / Gilead
ACTRN12606000446561: DORADO-AC – Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Not yet recruiting
3
800
 
Myogen, Inc., Myogen, Inc.
Resistant Hypertension
 
 
ACTRN12606000292572: DORADO – Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Recruiting
3
350
 
Myogen, inc.
Resistant Hypertension
 
 
NCT00330369 / 2006-001898-25: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Completed
3
352
US, Canada, Europe, RoW
Darusentan, LU 135252, Darusentan Placebo
Gilead Sciences
Hypertension
01/09
01/09
NCT00389779: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Completed
3
849
US, Europe, RoW
Darusentan, LU 135252, Guanfacine, Darusentan Placebo
Gilead Sciences
Hypertension
08/09
08/09
2006-003548-42: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionA Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)

Completed
3
770
Europe
Darusentan, Estulic, LU 135252 or GS-9377, Capsule*, Estulic
Gilead Sciences, Inc.
Resistant hypertension
 
 
NCT00353574 / 2006-001899-20: DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

Terminated
3
282
US, Canada, Europe, RoW
Darusentan
Gilead Sciences
Hypertension
02/10
04/10
NCT00389675: DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Terminated
3
661
US, RoW
Darusentan, LU 135252, Guanfacine
Gilead Sciences
Hypertension
02/10
05/10
2006-003547-23: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant HypertensionA Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or MoreAntihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo

 
3
57
Europe
Darusentan, Estulic, LU 135252 and GS-9377, C02A C02, Estulic, Estulic
Gilead Sciences, Inc.
Resistant hypertension
 
08/09

Download Options